PD-1/PD-L1 Inhibitor Update

Sophia Humphreys, PharmD, MHA, BCBBS, CPGx

Sophia Humphreys, PharmD, MHA, BCBBS, CPGx

- Pharm.D. from University of Washington in 2000
- MHA from University of Cincinnati 2018
- BCBBS certified in 2022
- Certified pharmacogenomics specialist in 2024
- 24 years of specialized experience in the pharmaceutical industry, involving for-profit and non-profit organizations

Director, System Formulary Management and Clinical Programs Sutter Health, Pharmacy Division




Current PD-1 and PD-L1 Inhibitors

The old and famous:

- Pembrolizumab (2014)
- Nivolumab (2014)

Newer agents

- Cemiplimab-rwlc (2018)
- dostarlimab-gxly (2021)
- Nivolumab & Relatimab-rmbw combo (2022)
- Toripalimab-tpzi (2023)
- retifanlimab-dlwr (2023)
- Tislelizumab-jsgr (2024)



- Pembroliz umab (2014)
- Nivolumab (2014)



Cemiplimab -rwlc (2018)

dostarlimab-

gxly (2021)

Nivolumab &

Relatimab-

rmbw combo (2022) Toripalimabtpzi (2023)

retifanlimabdlwr (2023)

Tislelizumab

-jsgr (2024)

Financial Impact

Generic Name	2023 Sales (Million)	Est. LOE
Pembrolizumab	\$17,818	2028-2029
Nivolumab	\$6,168	12/22/2028
Nivolumab & Relatlimab-rmbw	\$686	03/18/2036
Cemiplimab-rwlc	\$599	09/18/2035 or later
Dostarlimab-gxly	\$150	08/22/2038
Retifanlimab-dlwr	\$1	03/22/2037
Toripalimab-tpzi	0	2036
<u></u>		
Tislelizumab-jsgr	0	2038

Nivolunab & Relatinab mobile cemplinab.wit Retifantinaboliwi Totifalinabtpli Penbioliumab Dostariimabeen^W Tistellaunabisel

2023 Sales (Million)

\$20,000 \$18,000 \$16,000 \$14,000 \$12,000 \$10,000 \$8,000 \$6,000 \$4,000 \$2,000 **\$0**

Biosimilar Pipeline for PD-1 Inhibitors

2 for nivolumab

7 for pembrolizumab

5 in Phase 3 trials

4 pre-clinical trials

Indication:

- 1 melanoma
- 4 NSCLC
- 4 pre-clinical trials no indications available

Non-Small Cell Lung Cancer

- A systematic review and meta-analysis
- 5893 patients with metastatic or locally advanced non-small cell lung cancer
- Single-agent ICI significantly improved overall survival (OS), progression-free survival (PFS), and health-related quality of life, with significantly less Grade 3 or 4 adverse events compared with platinum-based chemotherapy.
- Combination ICI therapy significantly improved OS with no difference in Grade 3 or 4 adverse events compared with platinum-based chemotherapy.
- The effect of combination ICI on PFS, overall response rate, and health-related quality of life was not reported.
- ICIs included in the studies were atezolizumab, avelumab, cemiplimab-rwlc, durvalumab, ipilimumab, nivolumab, and pembrolizumab.

Newer PD-1 & PD-I1 inhibitor indications

Cemiplimab-rwlc (2018, NCCN Category 1; Preferred for NSCLC)

- Cutaneous squamous cell carcinoma (CSCC)
- Skin Cancer (not otherwise classified): Basal cell carcinoma*
- Lung Cancer: Non-small cell lung cancer (NSCLC)

Dostarlimab-gxly (2021, NCCN Category 2a)

- Endometrial cancer
- Solid Tumor
 - accelerated approval
 - 16 types of dMMR tumor, included both endometrial and non-endometrial solid tumors

The PD-1 Inhibitor Subclass is Expanding Fast

Toripalimab-tpzi (2023, Class II a, first-line)

- Nasopharyngeal carcinoma, Metastatic or recurrent locally advanced disease;
 - First-line treatment in combination with CISplatin and gemcitabine
 - **Monotherapy** for Progression on or after platinum-containing chemotherapy


Retifanlimab-dlwr (2023, Class II b)


• Merkel cell carcinoma, Locally advanced, metastatic or recurrent

Tislelizumab-jsgr (March 2024, Class II a, second line)

- Unresectable or metastatic **esophageal squamous cell carcinoma** (ESCC) after prior therapy systemic chemotherapy that did not include a PD-1 or PDL-1 inhibitor.
- 1st line ESCC and gastric/gastric esophageal junction cancers (PDUFA 2H 2024)







Take Aways

PD-1 inhibitors may not have been made equal

More studies are necessary

More indications may come soon

Competition = price reduction?

Biosimilars to older PD-1 inhibitors are in the pipeline

Thank you and stay in touch

- Sophia Humphreys, Pharm.D. MHA, BCBBS
- Email: <u>Sophia.Humphreys@sutterhealth.org</u>
- Or <a>sophiazhumphreys@gmail.com
- Phone: (206)550-3904



References

- 1. Moore DC, Elmes JB, Arnall JR, Strassel SA, Patel JN. PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review. Int Immunopharmacol. 2024 Mar 10;129:111606. doi: 10.1016/j.intimp.2024.111606. Epub 2024 Feb 14. PMID: 38359661.
- Ferrara R, Imbimbo M, Malouf R, et al: Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Cochrane Databases Syst Rev 2020; (12):CD013257. <u>PubMed Abstract: http://www.ncbi.nlm.nih.gov/...</u>
- Sonbol MB, Riaz IB, Naqvi SAA, et al: Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a systematic review and network meta-analysis. JAMA Oncol 2020; 6(12):e204930. <u>PubMed Abstract: http://www.ncbi.nlm.nih.gov/...</u>
- 4. Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Desai AP, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Juloori A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Mullikin TC, Ng T, Owen D, Owen DH, Patel SP, Patil T, Polanco PM, Riess J, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory KM, Hang L. Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 May;22(4):249-274. doi: 10.6004/jnccn.2204.0023. PMID: 38754467.
- 5. Rajasekaran N, Wang X, Ravindranathan S, Chin DJ, Tseng SY, Klakamp SL, Widmann K, Kapoor VN, Vexler V, Keegan P, Yao S, LaVallee T, Khare SD. Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells. Cancer Immunol Immunother. 2024 Feb 24;73(3):60. doi: 10.1007/s00262-024-03635-3. PMID: 38400933; PMCID: PMC10894093.
- 6. Zhang L, Geng Z, Hao B, Geng Q. Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody. Cancer Control. 2022 Jan-Dec;29:10732748221111296. doi: 10.1177/10732748221111296. PMID: 35926155; PMCID: PMC9358212.